Kairos Pharma and Bayer Collaborate to Test ENV-105 with XOFIGO for Advanced Prostate Cancer

Kairos Pharma Ltd. (NYSE American: KAPA) has announced a strategic collaboration with Bayer to evaluate its lead antibody candidate, ENV-105 (carotuximab), in combination with Bayer’s XOFIGO® (radium-223 dichloride) for the treatment of metastatic castration-resistant prostate cancer involving bone. This partnership aims to address a critical unmet need in advanced prostate cancer, where treatment resistance often limits therapeutic options.

ENV-105 is a first-in-class CD105/BMP signaling inhibitor designed to overcome cancer drug resistance. It is currently being evaluated in Phase 1 and Phase 2 clinical trials. Interim Phase 2 data previously reported by the company showed a median progression-free survival of more than 13 months in prostate cancer patients. XOFIGO is the only FDA-approved alpha-emitting radiopharmaceutical for symptomatic bone metastases in this patient population, making the combination a potentially synergistic approach.

The collaboration will investigate whether ENV-105 can enhance and extend responses to XOFIGO by targeting CD105, a protein associated with treatment resistance following androgen receptor inhibition and radiation therapy. Preclinical studies have demonstrated ENV-105’s ability to re-sensitize tumors to radiation, and management believes combining the therapy with XOFIGO could provide a more durable treatment option for patients with advanced prostate cancer.

This partnership is significant because it combines two innovative mechanisms: ENV-105’s ability to reverse drug resistance and XOFIGO’s proven efficacy in treating bone metastases. If successful, the combination could offer a new standard of care for patients who have limited options after standard therapies fail.

For more details, the full press release is available at https://ibn.fm/emSc4. Additional updates on Kairos Pharma can be found in the company’s newsroom at https://ibn.fm/KAPA.